Drug intelligence / Profile preview

[18F]MK-3328

Development stage: Discontinued
Lead developer: Merck
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[18F]MK-3328 is a radioactive PET tracer developed for the visualization and quantification of amyloid plaques in the brain. It binds with high affinity to human amyloid plaques with an IC50 of 10.5 nM. The tracer demonstrates favorable kinetics with high brain uptake and good washout in normal rhesus monkey PET imaging studies. It shows low in vivo binding potential in white matter and cortical grey matter, making it a promising candidate for detecting amyloid plaques associated with Alzheimer's disease.

Other names: 5-[18F]Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on [18F]MK-3328.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]MK-3328.

Explore the full profile